Micaela Laber Harary

Drug Access and Affordability Initiative - Biosimilars payment policy & uptake - PDUFA/BsUFA reform - Accelerated approval

Value, Evidence, and Access Strategy Consulting for Life Sciences

Commercial Leadership Development Program, Oncology

•Market access, reimbursement, and health policy consulting services for biotechnology, pharmaceutical, and medical device clients •Strategy development surrounding Medicare, Medicaid, and commercial reimbursement policy •Congress & Centers for Medicare and Medicaid Services policy analysis relevant to reimbursement, market access, and payment reform; seasoned in: drug pricing policy, alternative payment models, biosimilars, Medicare Part B & Part D, inpatient and outpatient prospective payment systems, physician fee schedule, CPT, HCPCS, state Medicaid waivers, state legislation, telehealth, opioids, MedPAC, MACPAC, PTAC •Landscape analysis of payer coding and coverage policies to support execution of national drug and device launches •Weekly legislative and regulatory briefings to senior executives internally and externally

Held various positions in the admission office: senior interviewer, tour guide, student associate, multicultural advisory council ambassador.

Patient-led organization funding and enabling research into gene therapy treatments for sight loss (e.g. macular degeneration, diabetic retinopathy, retinitis pigmentosa).

Data consistency, compliance, internal audits

Extensive biology and chemistry coursework. Thesis: "The Politics of Biosimilars: Understanding Stakeholder Influence Over Complex Policy Problems"

Certificate: Public Health Economics Capstone: "Recommendations to Facilitate the Interchangeable Biosimilars Market in the US"

Track: Health, Technology, & Innovation Award: Danaher Case Competition 2020, earned 2nd place out of 62 teams